Today's Trend
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is receiving positive investor attention as a major European regulatory approval and favorable analyst commentary strengthen the company’s growth outlook. Shares are trading near their 52-week high, with the latest news providing additional momentum.
- The European Commission approved DAYBU® (trofinetide) as the first and only treatment authorized in the European Union for neurobehavioral symptoms associated with Rett syndrome. The approval covers adults and children aged five and older, giving ACADIA access to a significant new geographic market and potentially expanding the drug’s revenue opportunity. European Commission Approves DAYBU for Rett Syndrome
- Analyst sentiment improved after Citigroup raised its ACADIA price target from $39 to $40 and upgraded or reaffirmed the stock with a “Buy” rating. The new target implies approximately 30.8% upside from the referenced price, signaling confidence in ACADIA’s commercial and earnings prospects. Citigroup Raises ACADIA Price Target
- ACADIA received a consensus analyst recommendation of “Moderate Buy,” adding broader Wall Street support to the bullish case. ACADIA Receives Moderate Buy Consensus
- The reported short-interest update shows zero shares short both before and after the period, with a zero-day short-interest ratio and an undefined percentage change. Because the data appears inconsistent, it provides no meaningful signal about short-seller positioning.
The key catalyst is the EU DAYBU approval, which broadens ACADIA’s commercial opportunity. Investors will now watch for launch timing, reimbursement progress and the treatment’s European sales trajectory.